bpc 157 clinical trial dose human bpc-157 dosing protocol BPC-157 Dosing (Common Protocols) πΉ Oral / Subcutaneous β’ 500 mcg daily β’ Duration: 6 weeks πΉ Intramuscular / Peritendinous β’ 1 mg daily β’ Duration: 6 weeks β οΈ Note: Not approved bpc-157 human clinical trials dosing
Description
The Phase 2b data was real
Not all food has equal protective power when it comes to slowing alcohol absorption rate
Message and data rates may apply
It is equally important to inform your healthcare provider of any other medications that you are taking before starting this medication
